Alectinib Drug to Treat Non-Small-Cell Lung Cancer

Lung cancer or lung carcinoma is one of the most common and serious cancers worldwide. Lung cancer occurs due to an uncontrolled growth of abnormal cells either in single or both lungs, which usually affects older people. Patients with anaplastic lymphoma kinase (ALK)-postive non-small-cell lung cancer were treated in two separate groups with alectinib and crizotinib respectively, and found alectinib improved the symptoms of lung cancer much better when compared with crizotinib.